REDONDO BEACH, CA--(Marketwired - Dec 13, 2016) - SECFilings.com, a leading financial news and information portal offering free real time public company filing alerts, announces an article discussing Cell MedX Corp. (
Broadening the Focus Cell MedX Corp.'s discovery phase trial in February 2015 found that its eBalance Technology improved insulin sensitivity and upregulated glycolytic processes resulting in enhanced transport as well as utilization of glucose during a single treatment. With the diabetes devices market expected to reach $35.5 billion by 2024, according to Grand View Research , an approved product that increases insulin sensitivity could quickly become a blockbuster therapeutic device.
Since then, further investigations led the company to broaden its focus to include conditions like Parkinson's disease and high blood pressure, where the company believes microcurrent technology could prove efficacious. GBI Research believes that Parkinson's disease could be a $3.2 billion market by 2021, while Technavio expects hypertension drugs to generate more than $32 billion in sales by 2020. These are significant additional end markets for the company's breakthrough technology.
The company's short-term goal is to obtain approval for the eBalance technology to treat pain and address general wellness. The company aims to initially deploy pain management solutions utilizing qualified supervisory protocols, with advanced therapies for related conditions to be offered by clinicians. The team would then apply to market and distribute the device to treat a variety of other conditions -- including diabetes and Parkinson's disease -- on an individualized basis, employing appropriate supervisory protocols, while potentially partnering with research institutions to further develop areas of investigation into a number of conditions where the technology has shown potential for future use.
Innovative Technology Cell MedX Corp.'s eBalance Pro is based on a fully software-driven microcurrent technology. Using cutting-edge software, the device identifies specific frequencies for microcurrent application through the use of a bio-feedback algorithm that identifies and delivers personalized frequencies to provide optimal outcomes which address specific, and in most instances, painful conditions.
Upon the successful completion of the upcoming clinical trials, the eBalance Pro would be the only microcurrent therapy developed to treat specific medical conditions on an individualized basis. The software-driven nature of the device would also enable results to be achieved more quickly than the lengthy time required by currently available microcurrent devices typically marketed for physiotherapy purposes. If successful, the eBalance Pro would hold a significant competitive advantage when marketed as medical device specifically capable of addressing a growing list of conditions.
Microcurrent technologies have been shown to have potential benefits across a range of medical conditions. Several studies have acknowledged that microcurrents appear to play a significant role in the healing process and can promote healing in a variety of bone and skin lesions, while other studies have shown that microcurrents can have a significant impact on reducing lower back pain and other conditions.
Follow the link to read the full article : http://analysis.secfilings.com/articles/137-c...technology
Interested parties are encouraged to receive a free Company Analysis here : http://analysis.secfilings.com/companies/11-cell-medx-corp
Cell MedX Disclaimer: Except for the historical information presented herein, matters discussed in this release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. In particular, Cell MedX Corp. has not yet begun its clinical trials, which are pending Health Canada approval. There is no assurance that the results of Cell MedX Corp.'s clinical observational trials will be successful, or that it will be able to obtain licensing or approval from Health Canada, the FDA or any other regulatory agencies.
This article has not been reviewed by the FDA or Health Canada, nor has it been peer reviewed. The microcurrent devices and therapies are approved by the FDA for the treatment of pain, but they have not been approved for other uses. The use of a device for an off-label use by a physician is legal. The use of microcurrent stimulation discussed herein is only part of a comprehensive program for supporting overall health, and should not replace any treatment prescribed by your physician.
About SECFilings.com Founded in 2004, SECFilings.com provides free real time filing alerts to over 600,000 registered members and offers services to help public companies grow their audience of interested investors.
Disclaimer: Except for the historical information presented herein, matters discussed in this release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. In particular, Cell MedX Corp. has not yet begun its clinical trials, which are pending Health Canada approval. There is no assurance that the results of Cell MedX Corp.'s clinical observational trials will be successful, or that it will be able to obtain licensing or approval from Health Canada, the FDA or any other regulatory agencies. Emerging Growth LLC, which owns SECFilings.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. Emerging Growth LLC has been compensated $1,000 for the production and dissemination of this article. For full disclosure please visit: http://secfilings.com/Disclaimer.aspx .
Contact: Paul Archie 406 862 2242 parchie@secfilings.com
